Scotiabank raised the firm’s price target on Twist Bioscience (TWST) to $54 from $50 and keeps an Outperform rating on the shares. The company wrapped up FY24 on a strong note, beating consensus and guidance across the board, the analyst tells investors. Looking ahead, the firm expects the company to remain well-positioned to continue to outperform its peer group across multiple macro scenarios.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 55% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on TWST:
- Twist Bioscience price target raised to $48 from $46 at Baird
- Twist Bioscience Reports Record Revenue in 2024
- Twist Bioscience price target lowered to $52 from $55 at Barclays
- Spirit enters into bankruptcy proceedings, CVS names new directors: Morning Buzz
- Morning Movers: Liberty Energy, Tesla up after President-elect Trump alliance